Key Highlights:
Building on MarketScan’s trusted foundation, Truven is expanding the MarketScan Partner Ecosystem to enhance the clinical depth available to life sciences and health data analysts.
Laboratory and diagnostic results augment its closed-claims data in MarketScan® Research Databases with millions of objective clinical measures.
MarketScan has informed over 4,500 peer-reviewed studies across diverse disease areas for more than three decades, establishing MarketScan as one of the most widely published and trusted real-world data sources in healthcare.
ANN ARBOR, Mich., August 26, 2026 – Truven, a trusted leader in healthcare data and analytics, is expanding the clinical depth available to health data analysts through the MarketScan Partner Ecosystem.
By linking de-identified lab results to MarketScan’s robust claims databases, life sciences and healthcare organizations can generate richer clinical insights across a wide range of therapeutic areas with the rigor and reliability for which MarketScan is known.
By bringing objective laboratory results (e.g., viral loads, biomarker levels, genetic test results) together with MarketScan’s longitudinal claims evidence, clients can measure clinical response and progression, define more clinically precise patient populations, and connect those findings to treatment patterns, healthcare utilization, and actual cost over time.
“Expanded access to large volumes of lab and diagnostic results reflects how the MarketScan Partner Ecosystem is evolving to meet the growing demand for precise, clinically informed real-world evidence,” said John E. Linnehan, Vice President and Head of Real-World Data for Truven. “We’re giving clients more options to generate evidence with MarketScan, enriched with additional clinical depth when their research demands it.”
Through the MarketScan Partner Ecosystem, clients can access multiple fit-for-purpose datasets spanning ambulatory and specialty EHR data, inpatient and facility-level detail, laboratory and diagnostic results, patient-level data collected outside traditional care settings, and more.
Linking MarketScan claims data with lab results adds objective biomarkers that can, for example, help confirm disease severity and track meaningful clinical changes over time. This capability enables life sciences companies to more effectively address complex research topics such as:
Disease progression of neurological disorders:
Challenge: Claims data alone may not capture lab-based clinical endpoints, such as biomarkers of neurodegeneration or inflammation.
Benefit: By combining lab results with MarketScan’s claims, analysts can stratify patients by severity or biomarker status and then compare outcomes, resource utilization, or relapse rates across subgroups.
Autoimmune disease treatment response:
Challenge: Claims data alone may not capture laboratory tests like C-reactive protein (CRP) levels, autoantibody titers, or genetic markers, which are critical to gauging inflammation and disease activity.
Benefit: When analysts link lab and claims data for autoimmune conditions, they can observe how patients with different baseline inflammation levels progress, how quickly they achieve lab-defined remission under various therapies, and how these clinical changes translate into differences in healthcare utilization and costs.
By tapping into lab-linked real-world evidence through MarketScan, life sciences and diagnostics organizations can pursue evidence generation efforts with greater confidence that their results reflect clinical reality, across diverse patient populations and diseases.
MarketScan is among the most comprehensive longitudinal closed-claims datasets in the industry, capturing the full spectrum of healthcare utilization and costs across large, diverse U.S. populations. MarketScan data have been cited in more than 4,500 peer-reviewed publications, reflecting its broad acceptance by researchers, payers, and regulators. These studies span a vast array of disease areas, demonstrating the data’s versatility and scientific significance.
To learn more about how the MarketScan Partner Ecosystem can support your research needs, visit the MarketScan Partner Ecosystem webpage.
About Truven and MarketScan
Truven by Merative is a portfolio of healthcare data and analytics solutions, backed by deep healthcare expertise. We help organizations understand, enhance, and maximize healthcare data to drive better health and financial outcomes. Through best-in-class data quality and market-leading solutions like Health Insights, MarketScan, and Springbuk, Truven serves 7 of the top U.S. health plans, more than 40% of the Fortune 500, and the top global pharmaceutical companies. Learn more at merative.com/truven.